Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Asciminib (Scemblix)

decorative image of the issue cover

Published October 21, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Scemblix be reimbursed by public drug plans for the treatment of adults with newly diagnosed Philadelphia chromosome (Ph)-positive (which happens when a person has a changed chromosome called the Ph) chronic myeloid leukemia (CML) (a cancer of the bone marrow and blood cells) in the chronic phase (CP) (when the disease is present but usually progresses slowly and causes few or no symptoms) if certain conditions are met.
  • Scemblix should only be covered to treat adults with newly diagnosed Ph-positive CML who are in the CP, have a good performance status, and do not have T315I or V299L
  • Scemblix should only be reimbursed if it is prescribed by clinicians with expertise and experience in treating CML and the cost of Scemblix is reduced.